Back to Results
| First Page | Meta Content | |
|---|---|---|
 | Document Date: 2012-09-12 09:27:14Open Document File Size: 530,21 KBShare Result on FacebookCitySalvador / San Francisco / Lisbon / /CompanyNew York Times / UK Collaborative Group / /ContinentEurope / Africa / /CountrySwitzerland / Kenya / Uganda / Netherlands / /CurrencyUSD / /FacilityUniversity Medical Centre Rotterdam / Epidemiological Virology Rega Institute / Portugal Viktor Müller Institute of Biology Eötvös Loránd University Budapest / /IndustryTermAIDS treatment / transmission network / pharmaceutical industry / HIV prevention / sexual network / sexual contact network / /MedicalConditionHIV infection / spastic paraparesis / generalized epidemics / New HIV Infections A / HIV / ATLL / disease / epidemic / neglected disease / chronic fatigue syndrome / prostate cancers / primary XMRV infection / XMRV infection / epidemic control strategies / myelopathy / highly infectious / acute stage / pain / nonviral infections / wild-type infections / fatigue / HIV infections / faster disease / adult T-cell leukemia/lymphoma / diseases / CD4restricted HIV infection / epidemic management potential / AIDS / infection / prostate cancer / infections / /MedicalTreatmentantiretroviral treatment / antiretroviral therapy / circumcision / /OrganizationHungarian Scientific Research Fund / Outras Doenças Tropicais Instituto / University Medical Centre Rotterdam / Brazil Instituto / Brazil Clinical and Epidemiological Virology Rega Institute for Medical Research Leuven / Portugal Viktor Müller Institute of Biology Eötvös Loránd University Budapest / Hungary Test and Treat For Prevention / San Francisco MSM / Johan Van Weyenbergh LIMI-CPqGM Oswaldo Cruz Foundation / /PersonVan Dooren / Viktor Müller / Ana Abecasis / Charles A.B. Boucher / Ana B. Abecasis Centro de Malária / de Vijver / Johan Van Weyenbergh / /Productzidovudine / /ProvinceOrStateQuebec / /PublishedMediumNew York Times / /Technologydiagnostic tests / molecular evolution / simulation / /SocialTag |